Aetna CPB 0792 Updated: What Billing Teams Need to Know About Human Fibrinogen Concentrate Coverage in 2026

Aetna, a CVS Health company, has modified Clinical Policy Bulletin 0792, which governs coverage of human fibrinogen concentrates RiaSTAP and Fibryga, effective March 12, 2026. This update refines the medical necessity criteria, prior authorization requirements, and approved indications for both products under commercial medical plans. If your organization bills J7177 or J7178—or manages patients with congenital or acquired fibrinogen deficiency—this policy deserves immediate attention.

Field	Detail
Payer	Aetna
Policy	Human Fibrinogen Concentrate (RiaSTAP and Fibryga) — CPB 0792
Policy Code	CPB 0792
Change Type	Modified
Effective Date	2026-03-12
Impact Level	High
Specialties Affected	Hematology, cardiac surgery, obstetrics, hospital outpatient infusion, specialty pharmacy
Key Action	Confirm all fibrinogen concentrate orders are prescribed by or in consultation with a hematologist, and obtain precertification before administration for both Fibryga and RiaSTAP.

---

Aetna Fibrinogen Concentrate Coverage Policy 2026: What's Covered and Why It Matters

CPB 0792 draws a clear line between the two FDA-approved human fibrinogen concentrates—Fibryga (J7177) and RiaSTAP (J7178)—and does not treat them as interchangeable for coverage purposes. Each product has its own approved indications, and billing the wrong product for a given diagnosis will likely trigger a denial.

This distinction is operationally significant. A patient with acquired fibrinogen deficiency, for example, can qualify for Fibryga coverage under this policy—but that same diagnosis will not satisfy RiaSTAP's medical necessity criteria, which are limited to congenital fibrinogen deficiency. Understanding which drug maps to which indication before the order is placed is essential for clean claims.

---

Aetna Prior Authorization Requirements: Precertification for Both Products

Precertification is required for both Fibryga and RiaSTAP for all Aetna participating providers and members in applicable plan designs. There is no pathway to skip this step.

To obtain precertification, contact Aetna's Special Case Precert Unit at (855) 888-9046. Do not submit these drugs without prior authorization in place—retroactive authorization is rarely successful for specialty biologics at this price point.

---

Fibryga (J7177) Medical Necessity Criteria Under Aetna CPB 0792

Aetna considers Fibryga medically necessary for two indications:

#	Covered Indication Copy
1	Congenital fibrinogen deficiency — including afibrinogenemia and hypofibrinogenemia, for treatment of acute bleeding episodes (ICD-10: D68.2)
2	Acquired fibrinogen deficiency — for treatment of bleeding episodes (ICD-10: D68.4)

That's the full scope of approved coverage. Every other use of Fibryga is classified as experimental, investigational, or unproven. This includes off-label use in surgical bleeding prophylaxis, postpartum hemorrhage management, or disseminated intravascular coagulation (DIC) unless the patient also carries one of the two qualifying diagnoses.

Prescriber requirement: Fibryga must be prescribed by or in consultation with a hematologist. An order from a hospitalist or OB alone, without documented hematology involvement, will not satisfy this requirement.

Continuation of therapy: Reauthorization is available for members who continue to meet the initial criteria. This applies to new members requesting authorization as well—there is no grandfathering based on prior approvals under a different plan.

---

RiaSTAP (J7178) Medical Necessity Criteria Under Aetna CPB 0792

RiaSTAP has a narrower approved indication set—limited entirely to congenital fibrinogen deficiency—but it covers three distinct clinical scenarios:

1. Acute bleeding episodes in members with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia (ICD-10: D68.2)
2. Perioperative management of bleeding in members with a diagnosis of afibrinogenemia
3. Prophylaxis to reduce bleeding frequency in members with afibrinogenemia—this indication requires justification from the medical records

Note that acquired fibrinogen deficiency (D68.4) does not qualify for RiaSTAP coverage under this policy. If your facility stocks both products and uses them interchangeably in acquired deficiency cases, that practice will create denials for RiaSTAP claims.

Prescriber requirement: Same as Fibryga—hematologist involvement is mandatory.

Continuation of therapy: The reauthorization standard differs by indication. For prophylaxis in afibrinogenemia, members must demonstrate benefit from therapy—the policy specifically cites reduced frequency of bleeding episodes as the benchmark. For all other RiaSTAP indications, continuation requires meeting the same initial criteria used for first authorization.

---

Affected Codes

Covered HCPCS Codes (if selection criteria are met)

Code	Type	Description Copy
J7177	HCPCS	Injection, human fibrinogen concentrate (Fibryga), 1 mg
J7178	HCPCS	Injection, human fibrinogen concentrate, not otherwise specified, 1 mg [RiaSTAP]

Infusion Administration Codes Referenced in the Policy

Laboratory Codes Referenced in the Policy

Code	Type	Description Copy
85384	CPT	Fibrinogen; activity
85385	CPT	Fibrinogen; antigen

Key ICD-10-CM Diagnosis Codes

Note on cardiac surgery CPT codes (33120–33926): The policy references 37 cardiac surgery procedure codes as "other CPT codes related to the CPB." These represent clinical contexts where fibrinogen deficiency may arise—particularly in cardiopulmonary bypass cases—but they are contextual references, not independently covered codes for the drug itself.

---

What Your Billing Team Should Do

Copy Action Items

---